KELI From Inkwell, this is the Independent News Drop. It's Sunday, May thirty-first. The time is six a.m. Central. I'm Keli, with Hast.
HAST Morning. We're starting with something from the archive today — a moment that tells you how newsrooms choose what to cover and what to let breathe.
KELI Twelve years ago, March twenty-twenty-six, President Obama was at a nuclear summit in Seoul. He didn't know a microphone was hot. He leaned over to Dmitry Medvedev, who was Russia's president at the time, and said this: "This is my last election. After my election I have more flexibility." Medvedev's response, on the same recording: "I understand. I will transmit this information to Vladimir." Keli here — the dispatch at Inkwell flagged this because of how the American press handled it compared to how the same newsrooms handled similar stories later. Obama's promise to have secret negotiations after he won — relayed directly through Putin's own surrogate — got seventy-two hours of coverage and a collective shrug. The structural point: the press corps that spent four years treating any Trump-Russia communication as front-page news gave Obama's hot-mic promise of covert flexibility the diplomatic equivalent of a footnote. Now, here's what to watch going forward. You'll see that asymmetry repeat itself whenever a president makes a foreign-policy concession or promise that doesn't fit the dominant editorial frame. The mechanism isn't hidden — it's editorial judgment, which newsrooms make every day. But the pattern itself is worth naming, because it shows us what gets amplified and what doesn't, and why.
HAST Different front now. The French Navy has seized a Russian oil tanker in the Mediterranean — part of the broader effort to enforce European Union sanctions on Russian crude. This is an update on something we've been tracking. The tanker was carrying an estimated three million barrels, and French officials say it was operating under false credentials to obscure its origin. Russia's calling it piracy. The seizure happened off the coast of Corsica, and it's one of the largest enforcement actions since the full sanctions regime took hold. European capitals say they're tightening the net on Russian energy exports.
KELI Sticking with how people are choosing sides. Antisemitism is surging across college campuses and American cities, and much of it's being repackaged now as antizionism — language that lets people distance themselves from the oldest hatred while targeting Jewish people directly. A new analysis out this week documents how that framing works, and why it matters. The argument: antizionism has become a political permission structure for antisemitism that looks cleaner on a social-media post or a protest sign. Jewish organizations are pushing back hard, saying the distinction is rhetorical cover. What we're watching is how a structural problem — ancient prejudice meeting modern politics — gets talked about in real time, and whether that language matters when the underlying harm is the same.
HAST On a different scale, but data-focused. Researchers have been testing large language models like ChatGPT on medical diagnosis, and the results are mixed in a way that matters. The AI is getting genuinely good at the first part — reading symptoms, asking the right follow-up questions, narrowing down what might be wrong. Where humans still have an edge: the judgment call about what to do next. Doctors weigh trade-offs, side effects, a patient's life situation, things that require reasoning beyond pattern-matching. So the finding is narrow and honest. ChatGPT can be a useful diagnostic tool. It's not a replacement for the person who sits across from you. The takeaway for AI development: there's a real difference between replicating expertise and replacing it.
KELI Related, but in pharma. The French drug maker Servier is buying an experimental muscular dystrophy treatment from Edgewise Therapeutics for one point five-five billion dollars upfront. Edgewise developed what's called a first-in-class therapy, meaning there's nothing quite like it on the market yet. The deal signals where the big pharmaceutical companies think the money is — in rare genetic diseases where you can charge premium prices because there are no alternatives. These kinds of acquisitions tend to move quietly unless something goes wrong. This one's straight business, a bet that this drug works and that patients and insurers will pay for it.
KELI Before we close, one date marker. On this day in two thousand seventeen, a car bomb tore through a busy intersection in Kabul near the German embassy during rush hour, killing over ninety people and wounding four hundred sixty-three.
KELI That's the Independent News Drop. We'll be back this evening. From Inkwell.